Results 121 to 130 of about 1,093 (174)

Very late onset narcolepsy type 1: a case report and review of the literature. [PDF]

J Clin Sleep Med
Martens J, Van Den Bossche M.
europepmc   +1 more source

Fast-Forward: Automatic Assignment and Assessment of Bonded Parameters for the Martini Force Field. [PDF]

J Chem Inf Model
Brasnett C, Fidlin M, Duve T, Thallmair S, Marrink SJ, Grünewald F.   +5 more
europepmc   +1 more source

Pharmacological inhibition of histamine N-methyltransferase extends wakefulness and suppresses cataplexy in a mouse model of narcolepsy. [PDF]

Sleep
Naganuma F, Girgin B, Agu ABS, Hirano K, Nakamura T, Yanai K, Vetrivelan R, Mochizuki T, Yanagisawa M, Yoshikawa T.   +9 more
europepmc   +1 more source

The cost utility of pitolisant as narcolepsy treatment

Acta Neurologica Scandinavica, 2020
The cost-effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse, and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
Anne-Marie Landtblom, Laura Pirhonen Nørmark, Pontus Wasling   +2 more
exaly   +5 more sources

Pharmacokinetics of pitolisant in children and adolescents with narcolepsy

Sleep Medicine, 2020
To evaluate the pharmacokinetic profile and tolerability of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist, in children and adolescents with narcolepsy.This multicenter, open-label, single-dose study of pitolisant 17.8 mg enrolled patients aged 6 through 17 years with a diagnosis of narcolepsy. Blood samples were collected
Patricia Franco, Giuseppe Plazzi, Evelyne Jacqz-Aigrain   +2 more
exaly   +6 more sources

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial [PDF]

American Journal of Respiratory and Critical Care Medicine, 2020
: Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the ...
Valerie Attali, Johan Verbraecken, Jan Hedner   +2 more
exaly   +5 more sources

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study

Sleep, 2019
International audienceSTUDY OBJECTIVES:To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy.METHODS:This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth
Smaranda Leu-Semenescu, Isabelle Arnulf, Yves Dauvilliers   +2 more
exaly   +3 more sources

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]

Neurological Sciences, 2022
Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Giuseppe Plazzi, Rocco Liguori, Paola Proserpio   +2 more
exaly   +4 more sources